The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic / Mayo Medical School. The Center is made up of 428 members (net increase of 97 new members since 2003) from 55 departments based at 3 geographical sites (Rochester, MN - MCR; Jacksonville, FL - MCF; and Phoenix/Scottsdale, AZ - MCA). The goal of the MCCC is to provide the best cancer care today, while developing improved strategies for tomorrow, serving cancer patients throughout the U.S. and the world. MCCC has 12 research programs: Women's Cancer; Gastrointestinal Cancer; Prostate Cancer; Hematologic Malignancies; Neuro-oncology; Cancer Imaging; Cell Biology; Developmental Therapeutics; Immunology & Immunotherapy; Gene & Virus Therapy; Genetic Epidemiology & Risk Assessment; Cancer Prevention & Control. Research is facilitated by 15 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Tissue & Cell Molecular Analysis, Biospecimens Accessioning & Processing, Clinical Research Office; Transgenic & Gene Targeted Mouse Shared Resource, Protein Chemistry & Proteomics, Flow Cytometry/Optical Morphology, Electron Microscopy, Pharmacology, Gene & Virus Therapy, Cytogenetics, and Gene Analysis. Since the last renewal, MCCC has continued to grow with an increase in overall peer-reviewed funding from $77.6 million to $105.8 million and an increase in NCI funding from $56.3 million to $75.7 million. Of particular note is that, in addition to an increase in investigator-initiated grants, MCCC has 2 new SPOREs (Breast and Brain) and 2 new training grants. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Prostate, Multiple Myeloma, Pancreas), as well as several multidisciplinary (P01, N01, 2 U01s, and 2 U10s) and 4 training grants. Research productivity is demonstrated by a 28% increase in annual publications during this period, particularly high impact clinical and scientific publications. Since the last competitive renewal, MCCC has benefited from: 1) new facilities with a net increase in new lab space (>100,000 sq ft) as well as new inpatient / outpatient space; 2) increased institutional commitment with a) 11 new endowed professorships ($22M institutional / $22M philanthropic), b) salary / start-up funds for 15 new faculty, c) funds to enhance integration of MCCC across 3 sites ($7.6M), and d) funds to enhance accrual of underserved minorities to clinical trials at MCA and MCF ($13M over 5 years). During the past 5 years, Developmental Funds from CCSG have been leveraged to aid in faculty recruitment at each of the 3 sites. During the next 5 years, we have plans to expand genetics, lung cancer, and melanoma research.

Public Health Relevance

The Mayo Clinic Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical, and population sciences research relevant to cancer research conducted within Mayo Clinic. The Center's goal is to translate the discoveries in the laboratory into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. The ultimate goal is to relieve the burdens of illness in patients with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-34S1
Application #
7674209
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2009-02-28
Budget Start
2008-07-01
Budget End
2008-12-31
Support Year
34
Fiscal Year
2008
Total Cost
$49,999
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551

Showing the most recent 10 out of 1129 publications